FGL1
Alpha Lifetech can provide FGL1 corresponding products, help each customer's research and development.
01
Introduction To FGL1
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to FGL1 protein is a common target in medicine.
FGL1 belongs to the fibrinogen family and is highly homologous to the fibrinogen-subunit and subunit carboxyl-terminal amino acids, but it does not form the platelet binding site necessary for the fibrin clot, cross-link region, and thrombin GL1 consists of the coil domain (CCD) and fibrinogen-like domain (FD). Under normal physiological conditions, FGL1 protein is mainly secreted by hepatocytes and involved in its mitotic and metabolic functions. FGL1 has limited expression in most normal tissues but is upregulated in several human cancers and is associated with poor prognosis and treatment outcomes.
Function of Target FGL1
FGL1 is upregulated in human cancers, especially in non-small cell lung cancer. Endogenous FGL1 may participate in the regulation of autoimmunity and immune homeostasis but does not affect development and growth. FGL 1 is an inhibitory ligand of LAG-3, and blocking the FGL1-LAG 3 interaction can preferentially stimulate the expansion and activation of T cells in the tumor microenvironment to promote tumor immunity. The FGL1-LAG3 interaction is independent of the B7-H1-PD-1 pathway and may help to address the question of resistance to anti-PD therapy in human cancers.
Gene Pathway of Target FGL1
LAG3 / FGL1 activity is associated with immune cell infiltration, proliferation, and secretion. When LAG3 / FGL1 was coexpressed with PD-1, the cytokine production was enhanced. FBXO38 interacts with and ubiquitinates FGL1 to negatively regulate its stability and mediate the cancer immune response. Depletion of FBXO38 significantly increased the abundance of FGL1, which not only inhibited CD8T cell infiltration, and enhanced the immune escape of the tumor, but also increased inflammation. On the other hand, tumor-associated macrophages (TAM) activate NF-ĸB by secreting TNFα/IL-1β in the liver microenvironment and transcriptionally upregulating the expression of OTU deubiquitination enzyme 1 (OTUD1), thereby enhancing the stability of FG1 by deubiquitination. Disruption of the TAM-OTUD 1-FGL 1 axis inhibits metastatic tumor progression and synergizes with immune checkpoint blockade (ICB) therapy.
Fig 1: FGL1 Gene Pathway. (Reference source: Tian T, Xie X, Yi W, Zhou Y, et al,. FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell Rep. 2023 Nov 28;42(11):113362. )
Alpha Lifetech Can Provide
At present, various drugs targeting FGL1 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. FGL1 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, FGL1 protein products are also essential. Alpha Lifetech can provide FGL1 with corresponding products and help each customer's research and development. In addition, Alpha Lifetech also provides advanced expression systems and purification services to accelerate antibody research and development. Our synthesized antibody expression undergoes rigorous quality validation, including sequencing validation and functional expression analysis, to ensure high fidelity and performance. In addition, Alpha Lifetech provides customized solutions for recombinant proteins, such as codon optimization, promoter selection, and vector design, supplemented by downstream applications such as protein expression analysis to meet specific experimental needs.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64630 | 50ug,100ug,500ug | |
| ALP64540 | ALP64540-Recombinant Human FGL1 Protein, His Tag | 50ug,100ug,500ug |
| ALP64530 | ALP64530-Recombinant Cynomolgus Monkey FGL1 Protein, His Tag | 50ug,100ug,500ug |
| ALP64528 | ALP64528-Recombinant Human FGL1 Protein, Fc Tag | 50ug,100ug,500ug |
| ALP64527 | ALP64527-Recombinant Human Biotinylated FGL1 Protein, Fc Tag, Avi Tag | 50ug,100ug,500ug |
| ALP64526 | ALP64526-Recombinant Cynomolgus Monkey Biotinylated FGL1 Protein, Avi Tag, His Tag | 50ug,100ug,500ug |
| ALP64523 | ALP64523-Recombinant Human Biotinylated FGL1 Protein, Avi Tag, His Tag | 50ug,100ug,500ug |
Reference
[1] Tian T, Xie X, Yi W, Zhou Y, Xu Y, Wang Z, Zhang J, Lin M, Zhang R, Lv Z, Li X, Lv L, Xu Y. FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell Rep. 2023 Nov 28;42(11):113362.
[2] Li JJ, Wang JH, Tian T, Liu J, Zheng YQ, Mo HY, Sheng H, Chen YX, Wu QN, Han Y, Liao K, Pan YQ, Zeng ZL, Liu ZX, Yang W, Xu RH, Ju HQ. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer. Nat Commun. 2023 Oct 23;14(1):6690.
[3] Chen K, Li X, Shang Y, Chen D, Qu S, Shu J, Zhang M, Wang Z, Huang J, Wu M, Ming S, Wu Y. FGL1-LAG3 axis impairs IL-10-Producing regulatory T cells associated with Systemic lupus erythematosus disease activity. Heliyon. 2023 Oct 7;9(10):e20806.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102